LakeShore Current Deferred Revenue from 2010 to 2026
| LSBCF Stock | 0.26 0.14 35.00% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 1.3 M | Current Value 1.6 M | Quarterly Volatility 278.5 K |
Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 38.4 M, Interest Expense of 27.1 M or Selling General Administrative of 134.5 M, as well as many indicators such as Price To Sales Ratio of 3.38, Dividend Yield of 0.0 or PTB Ratio of 4.16. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
LakeShore | Current Deferred Revenue | Build AI portfolio with LakeShore Stock |
The Current Deferred Revenue trend for LakeShore Biopharma Co offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether LakeShore Biopharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest LakeShore Biopharma's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of LakeShore Biopharma Co over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. LakeShore Biopharma's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LakeShore Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
LakeShore Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 2,020,029 | |
| Geometric Mean | 1,998,531 | |
| Coefficient Of Variation | 13.78 | |
| Mean Deviation | 196,368 | |
| Median | 2,121,645 | |
| Standard Deviation | 278,453 | |
| Sample Variance | 77.5B | |
| Range | 985.6K | |
| R-Value | (0.57) | |
| Mean Square Error | 55.4B | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | (31,679) | |
| Total Sum of Squares | 1.2T |
LakeShore Current Deferred Revenue History
About LakeShore Biopharma Financial Statements
LakeShore Biopharma stakeholders use historical fundamental indicators, such as LakeShore Biopharma's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although LakeShore Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in LakeShore Biopharma's assets and liabilities are reflected in the revenues and expenses on LakeShore Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in LakeShore Biopharma Co. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.3 M | 1.6 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of LakeShore Biopharma Correlation against competitors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Can Biotechnology industry sustain growth momentum? Does LakeShore have expansion opportunities? Factors like these will boost the valuation of LakeShore Biopharma. Expected growth trajectory for LakeShore significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating LakeShore Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding LakeShore Biopharma requires distinguishing between market price and book value, where the latter reflects LakeShore's accounting equity. The concept of intrinsic value - what LakeShore Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push LakeShore Biopharma's price substantially above or below its fundamental value.
Understanding that LakeShore Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LakeShore Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LakeShore Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.